Clinical Trials

At Lehigh Valley Health Network, we are committed to providing our patients and community with the best possible care and treatments. Our research scientists are integrated with our clinical departments for a comprehensive, collaborative approach to research. Have a question about clinical trials? Contact the Network Office of Research and Innovation at 610-402-9543.

Showing 60 of 131 Clinical Trials

Clinical Research Trial

A092205 Head and Neck Cancers

Randomized Phase III Trial of Pembrolizumab vs. Pembrolizumab/Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Platinum Refractory Disease

Doctor(s) Running This Study
Maged F. Khalil, MD
Clinical Research Trial

A092205 Head and Neck Cancers

Randomized Phase III Trial of Pembrolizumab vs. Pembrolizumab/Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Platinum Refractory Disease

Doctor(s) Running This Study
Maged F. Khalil, MD
Clinical Research Trial

MyeloMATCH MM1OA-EA02

A Randomized Phase II Study of Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial

Doctor(s) Running This Study
Maged F. Khalil, MD
Clinical Research Trial

MyeloMATCH MM1OA-EA02

A Randomized Phase II Study of Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial

Doctor(s) Running This Study
Maged F. Khalil, MD
Clinical Research Trial

MyeloMATCH MM1YA-S01

A RANDOMIZED PHASE II STUDY COMPARING CYTARABINE + DAUNORUBICIN (7+3) VS (DAUNORUBICIN AND CYTARABINE) LIPOSOME, CYTARABINE + DAUNORUBICIN + VENETOCLAX, AZACITIDINE + VENETOCLAX, AND (DAUNORUBICIN AND CYTARABINE) LIPOSOME + VENETOCLAX

Doctor(s) Running This Study
Maged F. Khalil, MD
Clinical Research Trial

MyeloMATCH MM1YA-S01

A RANDOMIZED PHASE II STUDY COMPARING CYTARABINE + DAUNORUBICIN (7+3) VS (DAUNORUBICIN AND CYTARABINE) LIPOSOME, CYTARABINE + DAUNORUBICIN + VENETOCLAX, AZACITIDINE + VENETOCLAX, AND (DAUNORUBICIN AND CYTARABINE) LIPOSOME + VENETOCLAX

Doctor(s) Running This Study
Maged F. Khalil, MD
Clinical Research Trial

MyeloMATCH MM1YA-CTG01

A MEASURABLE RESIDUAL DISEASE (MRD) FOCUSED, PHASE II STUDY OF VENETOCLAX PLUS CHEMOTHERAPY FOR NEWLY DIAGNOSED YOUNGER PATIENTS WITH INTERMEDIATE RISK ACUTE MYELOID LEUKEMIA: A TIER 1 MYELOMATCH CLINICAL TRIAL

Doctor(s) Running This Study
Maged F. Khalil, MD
Clinical Research Trial

MyeloMATCH MM1YA-CTG01

A MEASURABLE RESIDUAL DISEASE (MRD) FOCUSED, PHASE II STUDY OF VENETOCLAX PLUS CHEMOTHERAPY FOR NEWLY DIAGNOSED YOUNGER PATIENTS WITH INTERMEDIATE RISK ACUTE MYELOID LEUKEMIA: A TIER 1 MYELOMATCH CLINICAL TRIAL

Doctor(s) Running This Study
Maged F. Khalil, MD